Linnaeus Therapeutics is developing small molecule agents for cancer treatment, informed by clinical observations that highlight the impact of gender and pregnancy history on cancer incidence and survival rates. The company focuses on identifying new therapeutic targets to enhance treatment efficacy for various cancers, including melanoma and pancreatic ductal adenocarcinoma.
Funding
$29.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers exhibit gender disparities in incidence and survival rates, with females often experiencing decreased incidence and improved survival for certain cancers like melanoma and pancreatic ductal adenocarcinoma. Current cancer treatments do not fully leverage these observed clinical differences related to gender and pregnancy history.
Solution
Linnaeus Therapeutics is developing small molecule agents targeting novel pathways informed by clinical observations of gender and pregnancy-related differences in cancer outcomes. Their lead compound, LNS8801, targets a unique mechanism of action to enhance treatment efficacy across various cancers. By identifying and exploiting these previously unaddressed therapeutic targets, Linnaeus aims to develop more effective and personalized cancer therapies. The company's approach focuses on translating clinical insights into targeted small molecule interventions.
Target Audience
The primary target audience includes patients with cancers such as melanoma and pancreatic ductal adenocarcinoma, as well as oncologists seeking more effective treatment options.
Features
- LNS8801: A novel small molecule in clinical development.
- Focus on therapeutic targets derived from clinical observations related to gender and pregnancy history in cancer.
- Development of targeted therapies for cancers including melanoma and pancreatic ductal adenocarcinoma.